vTv TherapeuticsFRA:5VT0 -3.38%35 3-Year ROIIC % is 82.70 as of Dec. 2025, which is 124% above its 10-year median of 36.89. GuruFocus rates FRA:5VT0 with a GF Score™ of 35/100 and a GF Value™ of €6,924.34. Among 1,321 Biotechnology companies, vTv Therapeutics ranks better than 76.61% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
vTv Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 82.70%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for vTv Therapeutics's 3-Year ROIIC % or its related term are showing as below:
FRA:5VT0's 3-Year ROIIC % is ranked better than 76.61% of 1321
companies
in the Biotechnology industry
Industry Median: -4.44
vs FRA:5VT0: 82.70
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
vTv Therapeutics 3-Year ROIIC % Related Terms
vTv Therapeutics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for vTv Therapeutics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5VT0 vs SMNR, CNTB, ENLV: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, vTv Therapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
vTv Therapeutics 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, vTv Therapeutics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where vTv Therapeutics's 3-Year ROIIC % falls into.
vTv Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -28.018 (Dec. 2025) - -21.278 (Dec. 2022) )
/
( 1.853 (Dec. 2025) - 13.77 (Dec. 2022) )
=
-6.74
/
-11.917
=
56.56%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
vTv Therapeutics (FRA:5VT0) has a 3-Year ROIIC % of 82.70 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on vTv Therapeutics and its competitors. This is 124% above median its historical median of 36.89. According to the industry distribution chart, vTv Therapeutics ranks #309 out of 1321 companies in the Biotechnology industry, placing it in the top 23.4%.
Is vTv Therapeutics' 3-Year ROIIC % too high?
vTv Therapeutics' current 3-Year ROIIC % of 82.70 is 124% above median its 10-year median of 36.89. Based on the distribution chart, vTv Therapeutics ranks #309 out of 1321 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, vTv Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' 3-Year ROIIC % compare to SMNR and CNTB?
According to the Biotechnology industry distribution chart, vTv Therapeutics ranks #309 out of 1321 companies for 3-Year ROIIC %. This places vTv Therapeutics in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on vTv Therapeutics and its competitors. vTv Therapeutics's current 3-Year ROIIC % is 82.70, which is 124% above median its own 10-year median of 36.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
vTv Therapeutics (FRA:5VT0) has a current 3-Year ROIIC % of 82.70. The stock's GF Value™ is €6,924.34, compared to a current price of €28.60 — trading 99.6% below its estimated fair value. The current 3-Year ROIIC % is 82.70, which is 124% above median its 10-year median of 36.89. vTv Therapeutics' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For vTv Therapeutics (FRA:5VT0), the current 3-Year ROIIC % is 82.70 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is vTv Therapeutics (FRA:5VT0) Overvalued in 2026?
Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued.
The current stock price of €28.60 is trading 99.6% below its estimated GF Value™ of €6,924.34.
Key valuation signals for FRA:5VT0:
3-Year ROIIC %: 82.70 (124% above median its 10-year median of 36.89)
GF Value™: €6,924.34 vs. price of €28.60 (99.6% below fair value)
No single metric tells the full story. See the FRA:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score
Get the complete analysis for FRA:5VT0
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5VT0 has been successfully added to your 
